Drugs / Vitamin-K antagonist at INR 2-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00684307 | Feb 2007 → Jun 2008 | atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin-K antagonist at INR 2-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00684307 ↗ |
| Route | Oral | “Tablet, PO for a period of 3-9 months.” NCT00684307 ↗ |